Idiopathic copper-associated cirrhosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Idiopathic copper-associated cirrhosis.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Dificid

Cubist Pharmaceuticals LLC, a subsidiary of Merck Sharp & Dohme LLC

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Dificid

(fidaxomicin)Orphan drugstandard

Cubist Pharmaceuticals LLC, a subsidiary of Merck Sharp & Dohme LLC

Macrolide Antibacterial [EPC]

12.1 Mechanism of Action Fidaxomicin is an antibacterial drug [see Microbiology (12.4) ] .

FDA label ↗

MAVYRET

(glecaprevir and pibrentasvir)Orphan drugstandard

AbbVie, Inc.

Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]

12.1 Mechanism of Action Mechanism of Action MAVYRET is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral ag...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Idiopathic copper-associated cirrhosis.
Search all trials →
Search clinical trials for Idiopathic copper-associated cirrhosis

Recent News & Research

No recent news articles indexed yet for Idiopathic copper-associated cirrhosis.
Search PubMed for Idiopathic copper-associated cirrhosis

Browse all Idiopathic copper-associated cirrhosis news →

Specialist Network

No specialists currently listed for Idiopathic copper-associated cirrhosis.

View all Idiopathic copper-associated cirrhosis specialists →

Quick Actions